Status:
UNKNOWN
Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood
Lead Sponsor:
Biosolution Co., Ltd.
Conditions:
Burn Wound
Eligibility:
All Genders
1-70 years
Phase:
PHASE3
Brief Summary
The efficacy and safety of Autologous cultured keratinocyte cell on severe burn wound.
Eligibility Criteria
Inclusion
- Age : 1\~70 years
- More than 30% TBSA of second degree burn or more than 10% TBSA of third degree burn
- Must provide signed informed consent prior to participation in any study-related procedures
Exclusion
- Have a pyogenic infection
- Part of the facial cosmetic surgery cost
- Hypersensitivity reactions in patients with bovine proteins
- Hypersensitivity reactions in patients with Gentamycin
- Pregnancy or lactation
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2010
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00978705
Start Date
November 1 2007
End Date
January 1 2010
Last Update
September 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hangang Sacred Heart Hospital
Seoul, South Korea, 150-030